In pharmaceutical development, the journey from an Active Pharmaceutical Ingredient (API) to real-world therapeutic efficacy is shaped by countless variables. Among them, particle size stands out as one of the most critical, yet often underestimated, determinants of performance. At the microscopic level, how an API is engineered directly influences how it behaves in the body.

For inhalation and topical therapies in particular, particle size is far more than a manufacturing parameter. It governs dissolution rate, bioavailability, deposition, and dose uniformity, ultimately shaping patient response. APIs such as fluticasone propionate and mometasone furoate demonstrate how tightly controlled particle size can enable faster dissolution, predictable absorption, and consistent therapeutic outcomes across batches.

Precision micronisation plays a pivotal role in achieving this control. Uniform particle size distribution ensures formulation stability, reliable delivery to the intended site of action, and reproducible performance at scale. In inhalation therapies, it can determine how deeply particles deposit in the respiratory tract. In topical applications, it influences spreadability, penetration, and efficacy at the target site.

At Coral Drugs, scientific precision is applied where it matters most, at the microscopic level. Through specialised micronisation expertise and rigorous process control, APIs are engineered to meet exacting particle size specifications that translate into dependable, real-world results. This focus on particle precision helps bridge the gap between complex chemistry and therapeutic reliability.

Because in modern pharmaceutical development, efficacy is not just about the molecule, it’s about how precisely that molecule is engineered to perform.

Follow Coral Drugs on LinkedIn to explore more insights on API science, particle engineering, and pharmaceutical innovation.

‍